183 related articles for article (PubMed ID: 38753753)
1. Theranostics in Neuroendocrine Tumors.
Mallak N; O'Brien SR; Pryma DA; Mittra E
Cancer J; 2024 May-Jun 01; 30(3):185-193. PubMed ID: 38753753
[TBL] [Abstract][Full Text] [Related]
2. Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
Kaemmerer D; Peter L; Lupp A; Schulz S; Sänger J; Prasad V; Kulkarni H; Haugvik SP; Hommann M; Baum RP
Eur J Nucl Med Mol Imaging; 2011 Sep; 38(9):1659-68. PubMed ID: 21626438
[TBL] [Abstract][Full Text] [Related]
3. Performance of 177Lu-DOTATATE-based peptide receptor radionuclide therapy in metastatic gastroenteropancreatic neuroendocrine tumor: a multiparametric response evaluation correlating with primary tumor site, tumor proliferation index, and dual tracer imaging characteristics.
Thapa P; Ranade R; Ostwal V; Shrikhande SV; Goel M; Basu S
Nucl Med Commun; 2016 Oct; 37(10):1030-7. PubMed ID: 27243215
[TBL] [Abstract][Full Text] [Related]
4. Current status and future of targeted peptide receptor radionuclide positron emission tomography imaging and therapy of gastroenteropancreatic-neuroendocrine tumors.
Grey N; Silosky M; Lieu CH; Chin BB
World J Gastroenterol; 2022 May; 28(17):1768-1780. PubMed ID: 35633909
[TBL] [Abstract][Full Text] [Related]
5. Detection of somatostatin receptor subtypes 2 and 5 by somatostatin receptor scintigraphy and immunohistochemistry: clinical implications in the diagnostic and therapeutic management of gastroenteropancreatic neuroendocrine tumors.
Sclafani F; Carnaghi C; Di Tommaso L; Rodari M; Destro A; Rimassa L; Giordano L; Chiti A; Roncalli M; Santoro A
Tumori; 2011; 97(5):620-8. PubMed ID: 22158494
[TBL] [Abstract][Full Text] [Related]
6. Molecular Imaging and Therapy for Neuroendocrine Tumors.
Desai H; Borges-Neto S; Wong TZ
Curr Treat Options Oncol; 2019 Aug; 20(10):78. PubMed ID: 31468190
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tumor theranostics.
Ichikawa Y; Kobayashi N; Takano S; Kato I; Endo K; Inoue T
Cancer Sci; 2022 Jun; 113(6):1930-1938. PubMed ID: 35271754
[TBL] [Abstract][Full Text] [Related]
8. Peptide receptor radionuclide therapy implementation and results in a predominantly gastrointestinal neuroendocrine tumor population: A two-year experience in a nonuniversity setting.
Mejia A; Vivian E; Nwogu C; Shah J; Longoria R; Vo A; Shahin I; Verma J; Bageac A
Medicine (Baltimore); 2022 Mar; 101(9):e28970. PubMed ID: 35244064
[TBL] [Abstract][Full Text] [Related]
9. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
Perez K; Chan J
Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
[TBL] [Abstract][Full Text] [Related]
10. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice.
Sheikhbahaei S; Sadaghiani MS; Rowe SP; Solnes LB
AJR Am J Roentgenol; 2021 Aug; 217(2):495-506. PubMed ID: 34076455
[No Abstract] [Full Text] [Related]
11. Somatostatin Receptor Expression in Lung Neuroendocrine Tumors: An Analysis of DOTATATE PET Scans.
Al-Toubah T; Montilla-Soler J; El-Haddad G; Haider M; Strosberg J
J Nucl Med; 2023 Dec; 64(12):1895-1898. PubMed ID: 37797976
[TBL] [Abstract][Full Text] [Related]
12. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy.
Oberg KE; Reubi JC; Kwekkeboom DJ; Krenning EP
Gastroenterology; 2010 Sep; 139(3):742-53, 753.e1. PubMed ID: 20637207
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin A level-positive neuroendocrine differentiation.
Jois B; Asopa R; Basu S
Clin Nucl Med; 2014 Jun; 39(6):505-10. PubMed ID: 24662668
[TBL] [Abstract][Full Text] [Related]
14. [Gastroenteropancreatic neuroendocrine tumors : targeted diagnostics and therapy].
Holzer K
Chirurg; 2014 Aug; 85(8):731-44. PubMed ID: 25103842
[TBL] [Abstract][Full Text] [Related]
15. Impact of initial imaging with gallium-68 dotatate PET/CT on diagnosis and management of patients with neuroendocrine tumors.
Crown A; Rocha FG; Raghu P; Lin B; Funk G; Alseidi A; Hubka M; Rosales J; Lee M; Kennecke H
J Surg Oncol; 2020 Mar; 121(3):480-485. PubMed ID: 31853990
[TBL] [Abstract][Full Text] [Related]
16. Gastroenteropancreatic Neuroendocrine Tumors.
Cives M; Strosberg JR
CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
[TBL] [Abstract][Full Text] [Related]
17. Somatostatin Receptor Imaging and Theranostics: Current Practice and Future Prospects.
Park S; Parihar AS; Bodei L; Hope TA; Mallak N; Millo C; Prasad K; Wilson D; Zukotynski K; Mittra E
J Nucl Med; 2021 Oct; 62(10):1323-1329. PubMed ID: 34301785
[TBL] [Abstract][Full Text] [Related]
18. Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy.
Pencharz D; Gnanasegaran G; Navalkissoor S
Br J Radiol; 2018 Nov; 91(1091):20180108. PubMed ID: 30102557
[TBL] [Abstract][Full Text] [Related]
19. The Search for an Alternative to [
Waldmann CM; Stuparu AD; van Dam RM; Slavik R
Theranostics; 2019; 9(5):1336-1347. PubMed ID: 30867834
[TBL] [Abstract][Full Text] [Related]
20. Molecular imaging Theranostics of Neuroendocrine Tumors.
Fortunati E; Bonazzi N; Zanoni L; Fanti S; Ambrosini V
Semin Nucl Med; 2023 Jul; 53(4):539-554. PubMed ID: 36623974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]